98%
921
2 minutes
20
Background: Fracture Risk Assessment Tool (FRAX) is a fracture prediction tool that uses clinical risk factors with or without bone mineral density (BMD). BMD is difficult to obtain in resource-limited setting. Hence, we aimed to compare fracture risk prediction by FRAX without BMD (FRAX) and FRAX with BMD (FRAX/BMD).
Objective: We intended to determine if FRAX and FRAX/BMD would produce identical predictions for 10-year probability of hip fracture and major osteoporotic fracture (MOF). We also desired to study the risk factors that could help to identify the similarity of risk prediction.
Materials And Methods: A retrospective review of patients who underwent BMD measurement and FRAX assessment was conducted. Men and women >50 years of age with osteopenia and osteoporosis according to the World Health Organization (WHO) definition at one or more sites were included. FRAX prediction scores were calculated with and without BMD using the FRAX India tool.
Results: Of 239 subjects, 207 (86.61%) had identical fracture risk predictions with or without BMD in FRAX estimation. Mean age was lower ( = 0.009), whereas body mass index (BMI), hip BMD, spine BMD, and history of previous fracture were higher ( = 0.005, < 0.001, < 0.001, and = 0.02, respectively) in the identical prediction group.
Conclusion: In our study, FRAX provided fracture risk prediction alike FRAX/BMD in most of the cases. FRAX is a good predictor of fractures especially in younger patients with higher BMI. Therefore, we conclude that FRAX is an effective tool to predict osteoporotic fracture risk and would be an inexpensive alternative when access to dual-energy X-ray absorptiometry (DXA) is limited.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330847 | PMC |
http://dx.doi.org/10.4103/ijem.IJEM_412_18 | DOI Listing |
Eur J Case Rep Intern Med
August 2025
General medicine department, Universidad de Cartagena, Cartagena, Colombia.
Background: Romosozumab is a sclerostin-inhibiting monoclonal antibody that is effective and safe for anabolic treatment in patients with osteoporosis. Its main adverse effects are local; the severity of these injection-site reactions in clinical trials was generally mild.
Case Report: We present a case of a 71-year-old Colombian woman with osteoporosis at very high risk of fractures with no relevant history of drug allergies.
Background: Anticonvulsants are widely used in treating patients with mental and neurological disorders. Their long-term use increases the risk of a decrease in bone mineral density (BMD) and low-energy fractures. Despite the growing number of studies of drug-induced osteoporosis, the effect of anticonvulsants on bone microarchitecture remains poorly studied.
View Article and Find Full Text PDFJB JS Open Access
September 2025
University of Glasgow, Glasgow, United Kingdom.
Background: Open fractures are common and severe injuries that are associated with poor functional outcomes and quality of life, and high societal costs. Several classifications systems have been developed to characterize these injuries, predict prognosis and plan treatment. We aimed to assess the agreement between open fracture classification and patient-reported function, fracture-related infection, and amputation.
View Article and Find Full Text PDFJ Rehabil Med Clin Commun
September 2025
Department of Medicine, Division of Endocrinology, Western University, London, Canada.
Objective: People who have experienced stroke are at a high risk for falls, fractures, and osteoporosis. Bone health post-stroke is often overlooked. The goal of this study was to understand current practice perspectives and barriers to bone health care post-stroke among physiatrists.
View Article and Find Full Text PDFClin Interv Aging
September 2025
Department for Orthopedics, Traumatology and Plastic Surgery, University Hospital, Leipzig, Germany.
Study Design: Systematic review.
Purpose: As the number of elderly increases, age-related changes of body composition like osteoporosis and sarcopenic muscle changes contribute to higher morbidity, less quality of life and higher health care costs. Data on the effect of muscle atrophy on osteoporotic vertebral fractures is limited.